Benitec Biopharma names EY auditor for fiscal 2027
Baker Tilly’s reports for fiscal 2025 and 2026 had no adverse or disclaimed opinions and were not qualified or modified.
Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary
Benitec Biopharma Inc. (BNTC) dismissed Baker Tilly US, LLP and appointed Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending June 30, 2027; EY’s formal engagement remains subject to completion of its client acceptance process. The company said the change followed a review of its auditor engagement as a matter of good corporate governance.
Baker Tilly had served since 2020. Its reports for fiscal years ended June 30, 2025 and 2026 had no adverse opinion or disclaimer and were not qualified or modified as to going concern, uncertainty, audit scope, or accounting principles. The company reported no disagreements with Baker Tilly that, if unresolved, would have required the auditor to refer to them in its report. The only reportable event was a material weakness in controls over share-based compensation calculations, which the company said it remediated as of June 30, 2026.
Positive
- None.
Negative
- Share-based compensation control weakness was remediated as of June 30, 2026.
